Metabolism open最新文献

{"title":"Unveiling the potential of natural compounds in the fight against obesity","authors":"Ziwen Jia, Sijia Lu, Suzhen Chen, Junli Liu","doi":"10.1016/j.metop.2024.100271","DOIUrl":"10.1016/j.metop.2024.100271","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100271"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000033/pdfft?md5=7ef5339e64f0d7a3686a524a20b3d926&pid=1-s2.0-S2589936824000033-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139457683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depletion of JunB increases adipocyte thermogenic capacity and ameliorates diet-induced insulin resistance","authors":"Qian Zhou,&nbsp;Suzhen Chen,&nbsp;Junli Liu","doi":"10.1016/j.metop.2024.100277","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100277","url":null,"abstract":"<div><p>Adipose tissue is a crucial metabolic organ in the human body. It stores and exerts distinct physiological functions in different body regions. Fat not only serves as a cushion and insulator but also stores energy and conveys endocrine signals within the body. There is a growing recognition that adipose tissue is an organ that is misunderstood and underestimated in contribution to human health and disease progression by regulating its size and functionality. In mammals, the adipose tissue reservoir consists of three functionally distinct types of fat: white adipose tissue (WAT), brown adipose tissue (BAT), and beige or inducible brown adipose tissue (iWAT), which exhibits thermogenic capabilities intermediate between the other two. Fat in different depots exhibits considerable differences in origin, characteristics, and functions. They vary not only in adipocyte lineage, properties, thermogenesis, and endocrine functions but also in their immunological functions. In a recent study published in Nature Metabolism, Zhang et al. investigated the role of JunB in the thermogenic capacity of adipocytes and its significance in obesity and metabolic disorders. The study revealed that JunB expression in BAT coexists with both low and high thermogenic adipocytes, indicating a fundamental feature of heterogeneity and plasticity within BAT. In summary, this article demonstrates that research targeting JunB holds promise for improving diet-induced obesity and insulin resistance, offering new avenues for treating metabolic disorders.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100277"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000094/pdfft?md5=c5c93f8c314ced6d2f4f5cd84007b160&pid=1-s2.0-S2589936824000094-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antidiabetic activity of the aqueous extract of Erigeron floribundus leaves in streptozotocin-induced type 1 diabetes model in Wistar rats","authors":"Boutou Masky ,&nbsp;Hamadjida Adjia ,&nbsp;David Miaffo ,&nbsp;Bibi Farouck Aboubakar Oumarou ,&nbsp;Harquin Simplice Foyet ,&nbsp;Kakesse Maguirgue ,&nbsp;Ernest Rodrigue Talla ,&nbsp;Angele Kopodjing Bello ,&nbsp;Christian Bonabé ,&nbsp;Fidèle Ntchapda","doi":"10.1016/j.metop.2024.100288","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100288","url":null,"abstract":"<div><h3>Backgroud</h3><p><em>Erigeron floribundus</em> is a herbaceous plant used in traditional Cameroonian medicine to treat diabetes mellitus. The aim of this study was to evaluate the antidiabetic properties of the aqueous extract of <em>E. floribundus</em> leaves (AEEF) in diabetic rats.</p></div><div><h3>Methods</h3><p>Diabetes was induced by a single intraperitoneal injection of streptozotocin (60 mg/kg) in normal rats fasted for 16 h. Subsequently, 30 diabetic male rats were divided into groups and treated orally for 21 days with distilled water (10 mL/kg), glibenclamide (3 mg/kg) and AEEF (300, 400, and 500 mg/kg). Body weight, food and water intake, blood glucose, insulin levels, lipid and oxidative profiles, as well as some markers of liver and kidney function were assessed. Histological sections of the rats' pancreas were taken.</p></div><div><h3>Results</h3><p>AEEF and glibenclamide significantly increased (p &lt; 0.001) body weight and decreased food and water intake in rats. A decrease in blood glucose (p &lt; 0.001) and an increase in insulin levels (p &lt; 0.001) were observed in the AEEF and glibenclamide groups. AEEF caused a significant (p &lt; 0.001) decrease in the levels of total cholesterol, LDL-c, triglycérides and coronary risk index (CRI), accompanied by a significant (p &lt; 0.001) increase in HDL levels and HOMA-β in rats. AEEF showed an improvement (p &lt; 0.001) in CAT and SOD activity and GSH levels accompanied by a significant decrease (p &lt; 0.001) in malondialdehyde levels. In addition, ALAT and ASAT activity, urea and creatinine levels were significantly reduced (p &lt; 0.001) after treatment with AEEF and glibenclamide. The extract also improved the size of Langerhans Islets in the pancreas of diabetic rats.</p></div><div><h3>Conclusion</h3><p>AEEF contains several bioactive compounds conferring antidiabetic, anti-dyslipidemic and antioxidant properties, thus justifying its therapeutic use in the treatment of diabetes mellitus.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100288"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000203/pdfft?md5=22b5e81aeb49ac294a27975b00ff4ad9&pid=1-s2.0-S2589936824000203-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141163789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Once-weekly insulin icodec versus once-daily long-acting insulins for type 2 diabetes mellitus: Systematic review and meta-analysis","authors":"Sandro Augusto Goncalves Ribeiro ,&nbsp;Matheus Pedrotti Chavez ,&nbsp;Larissa Calixto Hespanhol ,&nbsp;Caroline Cristine Almeida Balieiro ,&nbsp;Eric Paqualotto ,&nbsp;Rodrigo Ribeiro e Silva ,&nbsp;Mateus Gauza ,&nbsp;João Roberto de Sa","doi":"10.1016/j.metop.2024.100285","DOIUrl":"10.1016/j.metop.2024.100285","url":null,"abstract":"<div><h3>Background</h3><p>Insulin icodec is a novel, long-acting, once-weekly basal insulin analog. Its comparative efficacy and safety with basal once-daily insulins in type 2 diabetes mellittus is uncertain.</p></div><div><h3>Objective</h3><p>Evaluate potential efficacy, benefits and risks associated with icodec compared to once-daily basal insulin analogs (degludec or glargine).</p></div><div><h3>Methods</h3><p>We systematically searched PubMed, Cochrane, and Embase for randomized controlled trials (RCTs) published until June 2023 comparing icodec versus long-acting insulin analogs (degludec and glargine) in type 2 diabetes mellitus (T2DM) with at least 12 weeks of follow-up. Binary endpoints were assessed with risk ratios (RRs) and continuous endpoints were compared using mean differences (MDs), with 95% confidence intervals (CIs). The protocol was registered in PROSPERO (CRD42023452468).</p></div><div><h3>Results</h3><p>A total of seven RCTs and 3286 patients with T2DM were included, of whom 1509 (60.6%) received icodec treatment. The follow-up period ranged from 16 to 78 weeks. Compared with once-daily basal insulin analogs, icodec led to a greater improvement in HbA1c (MD -0.15%; 95% CI -0.21, −0.10; p &lt; 0.0001; I² = 0%) and time in range (TIR) (MD 2.83%; 95%CI 0.94; 4.71; p = 0.003; I² = 22%). Body weight was increased with icodec treatment (MD 0.78 Kg; 95%CI 0.42, 1.15; p &lt; 0.01; I² = 86%). There was also a higher rate of injection site reactions (RR 1.89; 95%CI 1.12, 3.18; p = 0.016; I² = 0%) and nasopharyngitis (RR 1.94; 95%CI 1.11, 3.38; p = 0.020; I² = 0%) in the icodec group, compared with once-daily regimens. There was no significant difference between groups in fasting plasma glucose.</p></div><div><h3>Conclusions</h3><p>In this meta-analysis of RCTs, insulin icodec led to better control of HbA1c and TIR as compared with once-daily insulin regimens, albeit with increased weight gain and a higher rate of injection site reaction in the Icodec group.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100285"},"PeriodicalIF":0.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000173/pdfft?md5=73a126f4995fbfe901eb8c78fdbb4c27&pid=1-s2.0-S2589936824000173-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141137197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of antioxidant and antihyperglycemic effects Dovyalis Abyssinica (A. Rich)","authors":"Temesgen Baylie ,&nbsp;Wuhabie Tsega ,&nbsp;Mamaru Getinet ,&nbsp;Desalegn Abebaw ,&nbsp;Gashaw Azanaw ,&nbsp;Adane Adugna ,&nbsp;Mohammed Jemal","doi":"10.1016/j.metop.2024.100286","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100286","url":null,"abstract":"<div><h3>Background</h3><p>The leaves of <em>Dovyalis Abyssinica</em> have been used traditionally for the management of diabetes mellitus. Thus, this study aimed to evaluate the Antioxidant and Antihyperglycemic Effects of <em>Dovyalis Abyssinica</em> leaves crude extract in streptozotocin-induced diabetic mice.</p></div><div><h3>Methods</h3><p>To Evaluate the Antihyperglycemic, and Antioxidant Effects of Dovyalis Abyssinica Leaves Extract in Streptozotocin-Induced Diabetic Mice. Male Swiss albino mice were induced into diabetes using 100 mg/kg of streptozotocin. Mice were allocated randomly into six groups, six mice per group. The body weight and FBG measurements were done on days 0, 7th, 14th and 21st of treatment. Additionally, in vitro Antioxidant Activity of the Extract was determined using a DPPH assay. The data were entered into Epi-Data version 4.6, exported to SPSS version 26.0, and analysed by using a one-way ANOVA followed by a Tukey post hoc test, and P &lt; 0.05 was considered statistically significant.</p></div><div><h3>Results</h3><p>Dovyalis Abyssinica leaves crude extract showed significant (P &lt; 0.05-P&lt; 0.001) blood-glucose-lowering activity. Moreover, the crude extract of <em>D. abyssinica</em> reduced the fasting blood glucose level by 45.13 %, 52.51 %, 54.85 %, and 56.38 %, respectively, for DA 100, DA 200, DA 400, and GLC 5 mg/kg on the 21st day of treatment. After diabetic mice were treated with Dovyalis Abyssinica (100, 200, and 400 mg/kg) for 21 days, there was a significant increase in body weight as compared to diabetic control. Antioxidant activities of the leaf extract was found to be comparable to ascorbic acid with an IC50 of 140.04 μg/ml.</p></div><div><h3>Conclusion</h3><p>The present findings revealed that <em>D. abyssinica</em> leaves could be useful for the management of diabetes mellitus and other abnormalities related to this metabolic disorder. Thus, the present study may support the traditional use of <em>D. abyssinica</em> for diabetes mellitus treatment.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100286"},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000185/pdfft?md5=61ca06ffe8ac39dad3c85abde5ee4243&pid=1-s2.0-S2589936824000185-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141095905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the complex interplay of risk factors in type 2 diabetes mellitus: A comprehensive review","authors":"Samradhi Singh ,&nbsp;Mona Kriti ,&nbsp;Anamika K.S. ,&nbsp;Devojit Kumar Sarma ,&nbsp;Vinod Verma ,&nbsp;Ravinder Nagpal ,&nbsp;Dheeraj Mohania ,&nbsp;Rajnarayan Tiwari ,&nbsp;Manoj Kumar","doi":"10.1016/j.metop.2024.100287","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100287","url":null,"abstract":"<div><p>The complex and multidimensional landscape of type 2 diabetes mellitus (T2D) is a major global concern. Despite several years of extensive research, the precise underlying causes of T2D remain elusive, but evidence suggests that it is influenced by a myriad of interconnected risk factors such as epigenetics, genetics, gut microbiome, environmental factors, organelle stress, and dietary habits. The number of factors influencing the pathogenesis is increasing day by day which worsens the scenario; meanwhile, the interconnections shoot up the frame. By gaining deeper insights into the contributing factors, we may pave the way for the development of personalized medicine, which could unlock more precise and impactful treatment pathways for individuals with T2D. This review summarizes the state of knowledge about T2D pathogenesis, focusing on the interplay between various risk factors and their implications for future therapeutic strategies. Understanding these factors could lead to tailored treatments targeting specific risk factors and inform prevention efforts on a population level, ultimately improving outcomes for individuals with T2D and reducing its burden globally.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100287"},"PeriodicalIF":0.0,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000197/pdfft?md5=e5d645d78333644167b81b312309e521&pid=1-s2.0-S2589936824000197-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials","authors":"Hazem Ayesh ,&nbsp;Sajida Suhail ,&nbsp;Suhail Ayesh ,&nbsp;Kevin Niswender","doi":"10.1016/j.metop.2024.100284","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100284","url":null,"abstract":"<div><h3>Background</h3><p>Advancements in type 2 diabetes mellitus (T2DM) therapy, notably with weekly agents like glucagon-like peptide-1 receptor agonists (GLP-RAs) such as dulaglutide, offer promising outcomes in clinical practice. The emergence of once-weekly insulin adds to this therapeutic arsenal. This research aims to explore and compare the efficacy and safety profiles of these agents in diabetes management, facilitating informed decision-making for optimizing their utilization in clinical practice.</p></div><div><h3>Methods</h3><p>A systematic search of PubMed, Scopus, Cochrane, and Web of Science databases was conducted. The research protocol was registered at OSF registries (<span>https://osf.io/gd67x</span><svg><path></path></svg>). The primary outcome of interest was the change in hemoglobin A1C (HbA1c), with secondary outcomes including the change in fasting plasma glucose, body weight, prevalence of hypoglycemia, and treatment discontinuation due to adverse events. The evaluation of bias risk was conducted utilizing the RoB2 tool developed by the Cochrane Collaboration. Statistical analysis was performed using RStudio version 4.3.2 with the meta package version 7.0–0 and the netmeta package version 2.9–0. Confidence in network meta-analysis estimates was evaluated using the CINeMA (Confidence In Network Meta-Analysis). Heterogeneity was assessed by comparing the magnitude of the common between-study variance (τ2) for each outcome with empirical distributions of heterogeneity variances.</p></div><div><h3>Results</h3><p>Dulaglutide 1.5 mg (mg) weekly demonstrated superior reduction in hemoglobin A1C (HbA1c) compared to insulin, with a mean difference (MD) of −0.35 (95 % CI: −0.51 to −0.19). Additionally, Dulaglutide 1.5 mg exhibited greater weight loss, with an MD of −3.12 (95 % CI: −3.55 to −2.68). However, it also showed a higher rate of adverse events, with an odds ratio (OR) of 1.40 (95 % CI: 1.12 to 1.75) compared to insulin. Both doses of Dulaglutide (1.5 mg and 0.75 mg) had lower prevalence of hypoglycemia compared to insulin, with ORs of 0.60 (95 % CI: 0.41 to 0.87) and 0.59 (95 % CI: 0.41 to 0.86), respectively. There was no significant difference in treatment discontinuation among the treatment groups.</p></div><div><h3>Conclusion</h3><p>Dulaglutide, particularly at higher doses, demonstrates superior efficacy in lowering hemoglobin A1C and reducing hypoglycemia risk compared to Icodec insulin in type 2 diabetes management. However, its use is also associated with a higher incidence of adverse events. Clinicians should carefully consider these factors when selecting optimal treatment strategies for patients with type 2 diabetes mellitus.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100284"},"PeriodicalIF":0.0,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000161/pdfft?md5=15a7b5bbc46e7d4fd4fb792fda47e7a5&pid=1-s2.0-S2589936824000161-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140646401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study","authors":"Hala Zakaria,&nbsp;Sheikha Alshehhi,&nbsp;Milena Caccelli,&nbsp;Cigdem Ozkan,&nbsp;Judy Kattan,&nbsp;Zeinab Jafaar,&nbsp;Remie Laborte,&nbsp;Sofia Aleabova,&nbsp;Noah Almarzooqi,&nbsp;Ali Hashemi,&nbsp;Ihsan Almarzooqi","doi":"10.1016/j.metop.2024.100283","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100283","url":null,"abstract":"<div><h3>Aim</h3><p>Emerging anti-obesity pharmacotherapy provides an option to correct maladaptive physiological and hormonal changes associated with obesity. One of the widely used medications in this context is glucagon-like peptide 1 (GLP-1) agonists. However, the misuse of these medications without any guidance and monitoring of lifestyle modifications can lead to unfavorable outcomes. The study aims to evaluate the effectiveness of a hybrid care model, incorporating GLP-1 and GLP-1/GIP agonist therapies, in managing obese patients with/without pre-diabetes. This study showcases the midway results of a 6-month program, which includes a multidisciplinary care team and digital technology for continuous engagement and monitoring of patients, both in-clinic and remotely.</p></div><div><h3>Methods</h3><p>In a retrospective observational study, 115 participants were treated with GLP-1s (semaglutide, tirzepatide, and liraglutide). Physicians, dietitians, and coaches worked together to support behavioral changes using a dedicated app provided to patients. At the care team end, an integrated portal enabled continuous data flow allowing for the care team to provide personalized care via chat at regular intervals. Data collected included food logs, continuous glucose monitoring (CGM), and digital biomarkers such as sleep and activity.</p></div><div><h3>Results</h3><p>At the midpoint of the program, participants exhibited statistically significant improvements in various metabolic parameters. Mean weight reduction was 8 %, with significant reductions in BMI, fat mass, and cholesterol levels. 24 (20.9 %) of patients lost ≥5 % of body weight, 55 (47.8 %) patients lost ≥10 % weight, and 36 (31.3 %) patients lost ≥15 % weight. Sub-analysis of pre-diabetic patients (n=36) demonstrated substantial improvements, including control of pre-diabetes in 80.6 % of cases and reduced HbA1c levels back to normoglycemia (5.39 ± 0.27).</p></div><div><h3>Conclusion</h3><p>The Zone.Health's program, which combines pharmacotherapy with continuous engagement and monitoring to enable sustainable lifestyle modifications, demonstrated significant improvements in weight, body composition, and metabolic markers. Pre-diabetes was also effectively addressed. It is necessary to conduct further research to assess the long-term sustainability and optimal adoption of such care models into clinical practice.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100283"},"PeriodicalIF":0.0,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S258993682400015X/pdfft?md5=e450e26085fa4537a1557ae336a702d9&pid=1-s2.0-S258993682400015X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140646422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in glucose readings between the continuous glucose monitoring calibration free interstitial sensors versus capillary blood glucose monitoring by glucometer: An analysis of two cases","authors":"Phaik Ling Quah ,&nbsp;Sally Mun Hua Chai ,&nbsp;Kok Hian Tan","doi":"10.1016/j.metop.2024.100282","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100282","url":null,"abstract":"<div><h3>Aim</h3><p>To assess the differences in glucose readings between the continuous glucose monitoring calibration-free interstitial sensors versus capillary blood glucose monitoring by glucometer.</p></div><div><h3>Study design</h3><p>Two healthy non-pregnant volunteers participated in the study, and wore simultaneously both the calibration-free Freestyle Libre and the Dexcom G6 sensor. Glucose values were recorded before and after meals during breakfast, lunch, and dinner on three separate days by either scanning the Freestyle Libre CGM sensor with a smartphone, or obtaining glucose readings real-time through the Dexcom G6 CLARITY mobile application. Blood glucose values were recorded using the Accu-Chek Active glucose meter. The Wilcoxon signed-rank test was used for paired non-parametric data to compare glucose readings between groups.</p></div><div><h3>Results</h3><p>The average glucose values obtained from the Dexcom G6 CGM consistently registered higher (6.54 ± 0.80 mmol/L) and those from the Freestyle Libre (5.49 ± 0.65 mmol/L) consistently lower, from the glucometer (6.17 ± 0.55 mmol/L), with p-value &lt;0.05 between groups. In the three-way comparison, the Dexcom G6 CGM sensor yielded the highest values, followed by the glucose meter, and finally the Freestyle Libre CGM sensor</p></div><div><h3>Conclusion</h3><p>Both CGM systems exhibited discrepancies from blood glucose (BG) measurements, and variations were observed among the different CGM systems themselves.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100282"},"PeriodicalIF":0.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000148/pdfft?md5=10c1867844bdfaed4060c53c705bdd91&pid=1-s2.0-S2589936824000148-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140633334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific differences in the association between APOE genotype and metabolic syndrome among middle-aged and older rural Indians","authors":"Shilna Azhuvalappil ,&nbsp;Raghav Prasad ,&nbsp;Pravin Sahadevan ,&nbsp;Hitesh Pradhan ,&nbsp;Pooja Rai ,&nbsp;Jonas S. Sundarakumar","doi":"10.1016/j.metop.2024.100281","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100281","url":null,"abstract":"<div><h3>Background</h3><p>Metabolic syndrome (MetS), characterized by elevated blood pressure, high blood glucose, excess abdominal fat, and abnormal cholesterol or triglyceride levels, significantly increases the risk of various non-communicable diseases. This study focuses on understanding the sex-specific association between Apolipoprotein E (APOE) polymorphism and MetS among middle-aged and older adults in rural southern India.</p></div><div><h3>Methods</h3><p>This cross-sectional study utilized data from the Centre for Brain Research-Srinivaspura Aging, Neuro Senescence, and COGnition (CBR-SANSCOG) study. Participants (n = 3741) underwent comprehensive clinical assessments and blood investigations, including APOE genotyping. MetS was defined using the National Cholesterol Education Program – Adult Treatment Panel III (NCEP ATP III) and the Consensus criteria. Statistical analyses, including chi-square tests, ANCOVA, and logistic regression, were conducted to explore the association of APOE genotype with MetS and its components, stratified by sex.</p></div><div><h3>Results</h3><p>Females carrying the APOE E4 allele had 1.31-fold increased odds of MetS (95 % CI: 1.02,1.69, p = 0.035) according to the NCEP ATP III criteria but not when the Consensus criteria were applied. The study also noted sex-specific differences in the association of APOE with various MetS components, including lipid levels and waist circumference.</p></div><div><h3>Discussion</h3><p>Our findings reveal a sex-specific association between the APOE E4 allele and MetS, with only females having an increased risk. This study contributes to the understanding of the genetic underpinnings of MetS and highlights the importance of considering sex-specific differences in MetS research and its prevention strategies. This study underscores the complexity of MetS etiology and emphasizes the need for further research to elucidate the role of genetic, environmental, and lifestyle factors in its progression, particularly in sex-specific contexts.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100281"},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000136/pdfft?md5=8050e46bec5a44c2dbb105c5e875656c&pid=1-s2.0-S2589936824000136-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140552253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}